Biomarkers in Urine Samples From Patients With Wilms Tumor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01550393|
Recruitment Status : Completed
First Posted : March 12, 2012
Last Update Posted : July 11, 2016
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial studies biomarkers in urine from patients with Wilms tumor.
|Condition or disease||Intervention/treatment|
|Kidney Cancer||Genetic: proteomic profiling Other: enzyme-linked immunosorbent assay Other: laboratory biomarker analysis Other: medical chart review|
- To validate the prognostic performance of specific-candidate Wilms tumor markers by measuring their urinary concentration using enzyme-linked immunosorbent assays (ELISAs) in urine specimens collected at diagnosis from 50 patients with favorable histology Wilms tumor who relapsed and 50 patients who did not relapse.
OUTLINE: Urine specimens are analyzed using enzyme-linked immunosorbent assays (ELISAs) for biomarkers.
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Discovery and Validation of Wilms Tumor Markers Using Urine Proteomics|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||July 2016|
- Wilms tumor biomarkers identified by ELISA
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01550393
|Principal Investigator:||Elizabeth A. Mullen, MD||Dana-Farber Cancer Institute|